These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 36535197)

  • 21. Emerging Insights on the Diverse Roles of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Chronic Liver Diseases: Cholesterol Metabolism and Beyond.
    Grewal T; Buechler C
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35162992
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Physiology and role of PCSK9 in vascular disease: Potential impact of localized PCSK9 in vascular wall.
    Guo Y; Yan B; Gui Y; Tang Z; Tai S; Zhou S; Zheng XL
    J Cell Physiol; 2021 Apr; 236(4):2333-2351. PubMed ID: 32875580
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
    Urban D; Pöss J; Böhm M; Laufs U
    J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepatitis C virus and proprotein convertase subtilisin/kexin type 9: a detrimental interaction to increase viral infectivity and disrupt lipid metabolism.
    Pirro M; Bianconi V; Francisci D; Schiaroli E; Bagaglia F; Sahebkar A; Baldelli F
    J Cell Mol Med; 2017 Dec; 21(12):3150-3161. PubMed ID: 28722331
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel PCSK9 (Proprotein Convertase Subtilisin Kexin Type 9) Variants in Patients With Familial Hypercholesterolemia From Cape Town.
    Huijgen R; Blom DJ; Hartgers ML; Chemello K; Benito-Vicente A; Uribe KB; Behardien Z; Blackhurst DM; Brice BC; Defesche JC; de Jong AG; Jooste RJ; Solomon GAE; Wolmarans KH; Hovingh GK; Martin C; Lambert G; Marais AD
    Arterioscler Thromb Vasc Biol; 2021 Feb; 41(2):934-943. PubMed ID: 33147992
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Patients With
    Doi T; Hori M; Harada-Shiba M; Kataoka Y; Onozuka D; Nishimura K; Nishikawa R; Tsuda K; Ogura M; Son C; Miyamoto Y; Noguchi T; Shimokawa H; Yasuda S
    J Am Heart Assoc; 2021 Feb; 10(4):e018263. PubMed ID: 33533259
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of PCSK9 with inflammation and platelet activation markers and recurrent cardiovascular risks in STEMI patients undergoing primary PCI with or without diabetes.
    Song L; Zhao X; Chen R; Li J; Zhou J; Liu C; Zhou P; Wang Y; Chen Y; Zhao H; Yan H
    Cardiovasc Diabetol; 2022 May; 21(1):80. PubMed ID: 35596184
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The biological relevance of PCSK9: when less is better….
    Mbikay M; Chrétien M
    Biochem Cell Biol; 2022 Jun; 100(3):189-198. PubMed ID: 35263196
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PCSK9 and LRP5 in macrophage lipid internalization and inflammation.
    Badimon L; Luquero A; Crespo J; Peña E; Borrell-Pages M
    Cardiovasc Res; 2021 Jul; 117(9):2054-2068. PubMed ID: 32991689
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Proprotein Convertase Subtilisin-Kexin type-9 (PCSK9) and triglyceride-rich lipoprotein metabolism: Facts and gaps.
    Baragetti A; Grejtakova D; Casula M; Olmastroni E; Jotti GS; Norata GD; Catapano AL; Bellosta S
    Pharmacol Res; 2018 Apr; 130():1-11. PubMed ID: 29428206
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Proprotein convertase subtilisin/kexin type 9 (PCSK9) and metabolic syndrome: insights on insulin resistance, inflammation, and atherogenic dyslipidemia.
    Ferri N; Ruscica M
    Endocrine; 2016 Dec; 54(3):588-601. PubMed ID: 27038318
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors to Reduce Cardiovascular Inflammation and Outcomes.
    Liberale L; Montecucco F; Camici GG; Dallegri F; Vecchie A; Carbone F; Bonaventura A
    Curr Med Chem; 2017; 24(14):1403-1416. PubMed ID: 28260498
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The immune functions of PCSK9: Local and systemic perspectives.
    Liu X; Suo R; Chan CZY; Liu T; Tse G; Li G
    J Cell Physiol; 2019 Nov; 234(11):19180-19188. PubMed ID: 30950043
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mature proprotein convertase subtilisin/kexin type 9, coronary atheroma burden, and vessel remodeling in heterozygous familial hypercholesterolemia.
    Kataoka Y; Harada-Shiba M; Nakao K; Nakashima T; Kawakami S; Fujino M; Kanaya T; Nagai T; Tahara Y; Asaumi Y; Hori M; Ogura M; Goto Y; Noguchi T; Yasuda S
    J Clin Lipidol; 2017; 11(2):413-421.e3. PubMed ID: 28502498
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Beyond LDL: What Role for PCSK9 in Triglyceride-Rich Lipoprotein Metabolism?
    Dijk W; Le May C; Cariou B
    Trends Endocrinol Metab; 2018 Jun; 29(6):420-434. PubMed ID: 29665987
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PCSK9 Promotes Cardiovascular Diseases: Recent Evidence about Its Association with Platelet Activation-Induced Myocardial Infarction.
    Puteri MU; Azmi NU; Kato M; Saputri FC
    Life (Basel); 2022 Jan; 12(2):. PubMed ID: 35207479
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Role of PCSK9 in the Pathogenesis of Non-alcoholic Fatty Liver Disease and the Effect of PCSK9 Inhibitors.
    Theocharidou E; Papademetriou M; Reklou A; Sachinidis A; Boutari C; Giouleme O
    Curr Pharm Des; 2018; 24(31):3654-3657. PubMed ID: 30317984
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of Proprotein Convertase Subtilisin/Kexin Type 9 in the Pathogenesis of Graves' Orbitopathy in Orbital Fibroblasts.
    Lee GE; Kim J; Lee JS; Ko J; Lee EJ; Yoon JS
    Front Endocrinol (Lausanne); 2020; 11():607144. PubMed ID: 33488522
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Proprotein convertase subtilisin/kexin 9 V4I variant with LDLR mutations modifies the phenotype of familial hypercholesterolemia.
    Ohta N; Hori M; Takahashi A; Ogura M; Makino H; Tamanaha T; Fujiyama H; Miyamoto Y; Harada-Shiba M
    J Clin Lipidol; 2016; 10(3):547-555.e5. PubMed ID: 27206942
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PCSK9 targets important for lipid metabolism.
    Schulz R; Schlüter KD
    Clin Res Cardiol Suppl; 2017 Mar; 12(Suppl 1):2-11. PubMed ID: 28176216
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.